New drug combo aims to shrink untreatable liver tumors
Disease control
Not yet recruiting
This study tests whether adding an experimental drug called GKL-006 to a standard procedure (TACE) can shrink liver tumors that cannot be surgically removed. About 48 adults with advanced liver cancer will receive either the combination or TACE alone. The main goal is to see how …
Phase: PHASE2 • Sponsor: Beijing Gene Key Life Technology Co., Ltd • Aim: Disease control
Last updated May 12, 2026 13:41 UTC